With the signing of an equity agreement on April 2, 2025, biotech pioneers Repairon GmbH and life science investor Bioventure Management GmbH, both based in Göttingen, have entered into a strategic partnership with the potential to fundamentally change the treatment of heart failure worldwide. Bioventure is investing in Repairon – a spin-off from the University Medical Center Göttingen (UMG) – with the aim of supporting the clinical development and commercialization of its pioneering “heart patch” therapy.
Repairon was founded in 2014 by MBExC member Prof. Dr. Wolfram-Hubertus Zimmermann (UMG) and Dr. Lothar Germeroth. The company develops laboratory-produced, functional human heart muscle tissue – known as engineered human myocardium (EHM) – for the biological repair of damaged hearts. The technology, developed over decades at the UMG, is now in the clinical phase of the BioVAT-HF-DZHK20 trial and is being used for the first time in patients with severe heart failure.
Link to the GWG press release (in German)
Investment agreement between Repairon and Bioventure: (from left to right) Akos Farkas (Bioventure), Nico Straub (Bioventure), Dr. Lothar Germeroth, Dr. Erik Hoppe (Managing Director Bioventure), Prof. Dr. Wolfram-Hubertus Zimmermann (UMG). Photo: Kay Kirchwitz
